IRBM

Name ›

Address/P.O. Box › Postal Code/City › Country › Contact Person › Telephone › Email › Website › Social Media › Number of Employees › Founded (year) ›

Areas of Activity ›

iOmx Therapeutics AG

Fraunhoferstr. 13 82152 Martinsried Germany Dr Apollon Papadimitriou +49-89-8999-7090-0 info@iomx.com www.iomx.com

I

30 2016

| Next-generation cancer immunotherapies | Drug development | Immuno-oncology

First-in-class immuno-oncology drugs targeting novel cancer immune evasion mechanisms.

iOmx Therapeutics AG was founded in 2016 and focuses on the development of first-in-class, next-generation cancer immuno-therapy drugs, which are designed to neutralise the inhibitory function of novel tumour or tumour-associated myeloid cell-expressed immune- checkpoint modulators.

While the currently approved immune-checkpoint inhibitory drugs targeting CTLA-4, PD-1, or PD-L1 pathways have emerged as the standard of care in many tumour indications, they still do not meet the needs of most cancer patients, primarily due to inherent, nonredundant resistance mechanisms of tumours against immune cell attack.

Platform Overview

In order to discover and understand alternative druggable vulnerabilities in such immunosuppressive tumours, iOmx Therapeutics efficiently applies its proprietary iOTarg™ target discovery platform, a systematic highthroughput genetic screening approach, to identify and validate novel immune-checkpoint targets in cancer models that fail to respond to PD-L1 inhibition.

To date, this screening technology has been applied to several pairs of clinical tumour samples and tumourinfiltrating lymphocytes (TILs), resulting in the identification of multiple novel targets, which exhibit stronger inhibition of T cell-mediated killing than PD-L1 in classic assays.

To further extend the iOmx pipeline, an evolved version of the screening platform is currently being applied to identify and validate novel checkpoint targets in tumourassociated myeloid cells.

Overall, the iOTarg™ platform points the way to next-generation immunotherapy approaches that are designed to increase the clinical impact of immunecheckpoint therapies.

Pipeline

iOmx Therapeutics has identified multiple proprietary tumour-associated next-generation immune checkpoints and is advancing a preclinical-stage pipeline of promising drug candidates, which have the potential to address cancers that are resistant to current immunotherapies, including PD-1/PD-L1 checkpoint inhibitors.

Two highlights of the company’s pipeline are lead programme IMT-07 with OMX-0407, a small molecule sensitising tumour cells to the effect of immune-derived tumour necrosis factor (TNF) in the tumour microenvironment, and IMT-18 programme with a first-inclass IGSF11-targeting antibody, designed to eliminate tumour-induced immune suppression. For both programmes proprietary drug candidates with monotherapy potential have been identified and are currently in preclinical development. The company’s lead antibodies and kinase inhibitors have shown very promising single agent anti-tumour effects in multiple preclinical studies.

Outlook

iOmx Therapeutics will rapidly advance its promising pipeline through IND-enabling activities to clinical proofof concept for selected drug candidates. Lead product candidate OMX-0407 will enter clinical development in late 2022. Furthermore, new screens will deliver I/Oactive leads targeting novel myeloid checkpoints.